Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments

Importance of the Topic

This summary addresses the challenges and solutions in applying accurate-mass mass spectrometry workflows to biotherapeutic development, highlighting reproducibility and compliance in both regulated and non regulated settings.

Objectives and Study Overview

The study evaluates a bench top orthogonal acceleration time of flight LC MS platform named BioAccord. It aims to simplify instrument operation, automate data processing, and deliver high accuracy in intact protein, subunit, peptide mapping and released glycan analyses.

Methodology and Instrumentation

• Sample Preparation and Workflows
  • Intact Mass Analysis: mAbs and ADCs diluted in ammonium acetate with concentrations down to 1 ng per uL.
  • Subunit Analysis: IdeS digestion followed by forced oxidation to assess stability and oxidation products.
  • Peptide Mapping: Trypsin digestion with reduction and alkylation to achieve high sequence coverage.
  • Released Glycan Analysis: RFMS labeling using a glycan kit to detect N linked glycans.
• Instrumentation
  • UHPLC: Waters ACQUITY UPLC I Class PLUS with TUV or FLR detectors.
  • Mass Spectrometer: ACQUITY RDa oa TOF MS operating in MS and data independent acquisition modes.
  • Columns: BEH C4 for intact and subunit, BEH SEC for native SEC MS, BEH C18 for peptides, BEH Glycan Amide for glycans.
  • Software: UNIFI platform for automated acquisition, processing and reporting in a compliance ready environment.

Main Results and Discussion

• Intact Mass Analysis
  High resolution deconvoluted spectra for NIST mAb demonstrating mass accuracy and reproducible glycoform quantitation with RSD below 4 across over 300 injections.
• Subunit Analysis
  Detection of up to three oxidized species in both scFc and F(ab) subunits with maintained resolution and mass accuracy after forced degradation.
• Peptide Mapping
  Chromatograms showed high sequence coverage and accurate precursor and fragment mass measurements. DIA mode enabled reliable fragmentation spectra for peptide identification.
• Released Glycan Analysis
  Identification of 28 N linked glycans with 19 species above 0.1 percent abundance. Sensitivity allowed detection of low abundance glycans down to 0.09 percent with signal to noise ratio of 30.
• Antibody Drug Conjugate Analysis
  LC SEC MS deconvolution enabled clear detection of drug load distributions for T D M1, matching expected average DAR and correlating with orthogonal HIC results.

Benefits and Practical Applications

The BioAccord system provides an integrated automated workflow that reduces user complexity, improves reproducibility, and supports regulatory compliance. It can streamline multiple critical analyses in biotherapeutic development labs and QC environments.

Future Trends and Possibilities

Potential developments include expanded DIA capabilities, automated sample preparation modules, real time process monitoring, deeper integration with informatics platforms and application to a broader range of complex biologics.

Conclusion

The evaluated BioAccord oa TOF LC MS platform demonstrated high accuracy, robustness and ease of use across intact mass, subunit, peptide mapping and glycan analyses. The system holds promise for accelerating biotherapeutic characterization in regulated and non regulated environments.

References

Not provided in the source